Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Inhibikase Therapeutics (NASDAQ:IKT) from a strong sell rating to a sell rating in a research report report published on Sunday morning.

A number of other equities analysts have also recently issued reports on the company. LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, July 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Friday, July 17th. Finally, Oppenheimer started coverage on Inhibikase Therapeutics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $5.00 price target for the company. Four research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Inhibikase Therapeutics currently has an average rating of “Buy” and a consensus target price of $5.40.

Inhibikase Therapeutics Stock Performance

Shares of NASDAQ:IKT opened at $2.31 on Friday. The stock has a market capitalization of $304.99 million, a price-to-earnings ratio of -5.37 and a beta of 0.94. Inhibikase Therapeutics has a 1-year low of $1.33 and a 1-year high of $2.53. The company has a 50 day moving average price of $1.89 and a 200 day moving average price of $1.82.

Inhibikase Therapeutics (NASDAQ:IKT) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). On average, sell-side analysts expect that Inhibikase Therapeutics will post -0.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Inhibikase Therapeutics

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its position in shares of Inhibikase Therapeutics by 70.3% in the third quarter. BNP Paribas Financial Markets now owns 15,640 shares of the company’s stock worth $25,000 after buying an additional 6,458 shares during the period. Barclays PLC grew its holdings in shares of Inhibikase Therapeutics by 10.8% during the fourth quarter. Barclays PLC now owns 94,795 shares of the company’s stock valued at $194,000 after buying an additional 9,217 shares in the last quarter. Virtu Financial LLC raised its position in Inhibikase Therapeutics by 70.1% during the fourth quarter. Virtu Financial LLC now owns 22,869 shares of the company’s stock valued at $47,000 after buying an additional 9,423 shares during the period. Sanctuary Advisors LLC acquired a new position in Inhibikase Therapeutics during the fourth quarter valued at $26,000. Finally, SG Americas Securities LLC purchased a new stake in Inhibikase Therapeutics in the 1st quarter worth about $26,000. Hedge funds and other institutional investors own 3.81% of the company’s stock.

Inhibikase Therapeutics Company Profile

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.